Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.

ABSTRACT:

Introduction

Renal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostate-specific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular endothelial cells of many solid tumors, including metastatic RCC. Although studied in several small clinical studies, PSMA-based imaging and therapy have not been pursued rigorously in preclinical RCC. This study aimed to evaluate the preclinical performance of PSMA-based radiotheranostic agents in a relevant murine model.

Methods

A PSMA-overexpressing murine cell line, PSMA+ RENCA, was developed by lentiviral transduction. PSMA-based theranostic agents, ⁶⁸Ga-L1/¹⁷⁷Lu-L1/²²⁵Ac-L1, were synthesized in high radio

SUBMITTER: Singh R 

PROVIDER: S-EPMC11423292 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature